January 31, 2024
Supernus Pharmaceuticals Inc. v. Torrent Pharmaceuticals Ltd., et al., Nos. 21-06964 and 21-14268 (GC/DEA) (D.N.J.)
Following two-and-a-half years of litigation, a four-day bench trial, and extensive post-trial briefing, Judge Castner of the United States District Court for the District of New Jersey in a sealed 123-page opinion ruled that Torrent Pharmaceuticals Ltd. and a subsidiary infringed patents owned by Haug Partners client Supernus Pharmaceuticals, Inc. by seeking permission from FDA to market a generic version of Trokendi XR® before the expiration of Supernus’s patents. As part of the ruling, Judge Castner found all three asserted patents valid over multiple invalidity grounds argued by Torrent. Trokendi XR® is a once-a-day topiramate capsule used to treat epilepsy and migraines in adults and children. Haug Partners is particularly pleased to help protect this important Supernus franchise.